Most GLP-1 side effects are gastrointestinal — nausea, diarrhea, vomiting, mild upper-abdominal discomfort — and concentrate in the first 8 to 12 weeks during dose titration. The doctor-led 5-step titration protocol minimizes severity. This guide covers common effects, mitigation strategies, when to call your prescriber, and the FDA boxed warning every GLP-1 patient should understand.
Treatments supervised by Dr. Kenika Norrachetdecha
Medical Director · Thai License #72509
● Mon–Sat 8 AM–6 PM · Online consults daily · Reply in 2 Min
Personal consultation included with every program
That's −17.8 kg — you'd weigh .
Based on the 20.9% trial-mean. Individual outcomes vary.Frequencies below are taken directly from the SURMOUNT-1 (tirzepatide) and STEP-1 (semaglutide 2.4 mg) phase-3 trial publications. Most events are mild-to-moderate and concentrated in the first 8–12 weeks.
Source: Jastreboff et al. (NEJM 2022) · Wilding et al. (NEJM 2021). Frequencies rounded to nearest whole percent.
First-line management is dietary and behavioral. Medication adjustments are reserved for symptoms that disrupt daily life despite these measures.
TRT Bangkok patients have direct WhatsApp access during titration. The list below is the threshold for messaging right away — not waiting for the next scheduled check-in.
These events are uncommon but require immediate medical attention. Each entry includes the warning signs Dr. Kenika trains patients to recognise.
Severe upper-abdominal pain radiating to the back, persistent vomiting, fever. Stop the medication and go to the nearest ER.
Cholecystitis or cholelithiasis present as right-upper-quadrant pain, nausea after fatty meals, or jaundice. Imaging confirms.
Usually secondary to dehydration from persistent vomiting/diarrhea. Watch for reduced urine output and dark-coloured urine.
Hives, swelling of face/lips, difficulty breathing. Anaphylaxis is rare but possible — treat as a medical emergency.
GI side-effects are most intense during titration. By week 12 the body has adapted to the maintenance dose and most patients report symptom resolution.
Nausea, fatigue, and reduced appetite are at their highest. Dose escalations happen every 4 weeks. This is the most demanding phase.
GI symptoms taper. Most patients describe a clear improvement compared to week 1. Energy and food enjoyment begin returning.
Majority of patients are tolerant of the maintenance dose. Weight-loss trajectory becomes steady; side-effects are now occasional, not daily.
Pick your treatment, enter your weights, see your trajectory. All data from peer-reviewed clinical trials. Individual outcomes vary — final program plan determined in private consultation.
Your trajectory · based on clinical-trial mean
Side-effect data drawn from pivotal Phase 3 trials. SURMOUNT-1 (tirzepatide): nausea 24.6-33.0 percent, diarrhea 18.7-23.0 percent, vomiting 8.3-12.2 percent across doses. STEP-1 (semaglutide 2.4 mg): nausea 44.2 percent, diarrhea 31.5 percent, vomiting 24.8 percent. Boxed warning across all GLP-1 medications: thyroid C-cell tumors (rodent studies); contraindicated in MTC or MEN-2 patients. Report severe abdominal pain, persistent vomiting, or allergic reactions immediately.
Each program is personalized based on your profile, medical history, and goals.
Step 1 of 5
Step 2 of 5
Select all that apply, or "None of these"
Step 3 of 5
Confidential — only your doctor sees this
Step 4 of 5
Step 5 of 5
Dr. Kenika's recommendation for you
Your access
—
Our actual clinic · Real photos
Authentic medications. Direct access to Dr. Kenika. Comprehensive metabolic care beyond GLP-1 alone.
Authentic Medications
Mounjaro, Zepbound (Eli Lilly), Wegovy, Ozempic, Saxenda (Novo Nordisk) — all sourced through the licensed Thai pharmaceutical supply chain.
Direct Doctor Access
WhatsApp Dr. Kenika directly. Every GLP-1 prescription personally supervised by the Medical Director.
Beyond GLP-1
Multi-modal metabolic care: GLP-1 plus hormone optimization, IV recovery, and advanced peptide protocols.
In Thailand for treatment? For ongoing side-effect management, many patients prefer in-person follow-up. Our in-clinic in Pattaya location offers anti-emetic prescriptions, dose adjustments, and dietary coaching.
Gastrointestinal effects are most common in the first 8–12 weeks: nausea (30–40% of patients), diarrhea (15–25%), vomiting (10–15%), constipation (5–10%), abdominal discomfort. Most patients see symptoms ease as the body adjusts.
Eat smaller, more frequent meals. Avoid high-fat or spicy foods early in treatment. Stay well-hydrated (2+ L water daily). Take medication at night before sleep if morning nausea is severe. Most nausea improves after weeks 6–10.
Severe abdominal pain radiating to the back (possible pancreatitis), persistent vomiting (dehydration risk), yellow skin or eyes (gallbladder issues), severe allergic reactions, vision changes, or signs of thyroid problems (neck mass, dysphagia, persistent hoarseness).
All GLP-1 medications carry an FDA boxed warning: thyroid C-cell tumors observed in rodent studies. Contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
STEP-4 trial showed patients who stopped semaglutide regained approximately two-thirds of lost weight within one year. Obesity is a chronic condition requiring long-term treatment — similar to medications for hypertension or cholesterol.
Acute pancreatitis is rare but serious. Risk factors include personal history of pancreatitis, gallstones, heavy alcohol use, and high triglycerides. We screen during eligibility and monitor throughout treatment. Report severe abdominal pain immediately.
Some patients report mood changes. The FDA monitors this signal. If you notice depression, anxiety, or suicidal thoughts, contact Dr. Kenika immediately. Mental health monitoring is part of our ongoing care protocol.
Moderate alcohol is generally permitted but may worsen nausea, increase hypoglycemia risk, and slow weight loss. Heavy alcohol use significantly increases pancreatitis risk and is discouraged. Discuss with Dr. Kenika.
Licensed
Thai Pharmacy
Pharmaceutical
Grade
Doctor
Supervised
Same-Day
Care
Real reviews from real patients on Google Business Profile. Currently 5.0 ★ from 25 verified reviews — and growing. Reviews are updated regularly.
Peer-reviewed primary sources, FDA prescribing information, and manufacturer documentation.
Additional clinical questions are discussed during your private consultation with Dr. Kenika.
Direct access to Dr. Kenika. Authentic medications. Three access points across Thailand.
Personal medical supervision · Cancel anytime · Authentic medications from Eli Lilly and Novo Nordisk
Book via WhatsApp · Free eligibility check
Each GLP-1 protocol has a different mechanism, trial profile, and outcome ceiling. Compare or explore by location.
Eli Lilly's dual GIP/GLP-1 agonist. Highest trial-mean of any approved GLP-1. Best fit for goals above 15%.
See program →
Novo Nordisk's most-prescribed GLP-1. Excellent track record for goals up to 15%. Built-in outcome estimator.
See program →
Investigational GLP-1/GIP/Glucagon triple agonist. Highest documented mean reduction. Private-consultation program.
See program →
In-person consultation, baseline labs, and same-week start. Walk-in or appointment. Most international patients begin here.
See clinic →Most common GLP-1 receptor agonist adverse events reported in the STEP-1 trial (Wilding et al., NEJM 2021) and SURMOUNT-1 trial (Jastreboff et al., NEJM 2022) include nausea (44 percent), diarrhea (32 percent), vomiting (24 percent), and constipation (24 percent). Most events were mild to moderate severity and resolved within the first 4-8 weeks of dose escalation. Clinical management focuses on gradual dose titration, antiemetic support, dietary modification, and hydration. Serious adverse events occurred in less than 10 percent of trial participants.
Last reviewed by Dr. Kenika Tonkam, Medical Director, TRT Bangkok · June 3, 2026
